Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of metronomic capecitabine and fulvestrant in recurrent endometrial cancer after platinum-based chemotherapy
KCT0011179Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of capecitabine and fulvestrant in endometrial cancer (EC), sponsored by Boryung. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
capecitabinefulvestrant
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0011179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011179.